My watch list  


Systematic (IUPAC) name
CAS number 121679-13-8
ATC code N02CC02
PubChem 4440
DrugBank APRD00220
Chemical data
Formula C17H25N3O2S 
Mol. mass 335.465 g/mol
Pharmacokinetic data
Bioavailability 74%
Metabolism Hepatic
Half life 5-8 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

B3(AU) C(US)

Legal status

Prescription only

Routes Oral

Naratriptan (trade name Amerge) is a triptan drug developed by Glaxo Wellcome Inc. and is used for the treatment of migraine headaches. Naratriptan is available in 2.5 mg tablets. It is a selective 5-hydroxytryptamine1 receptor subtype agonist. Naratriptan hydrochloride is chemically designated as N-methyl-3-( 1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide.

Some side effects of the drug include vision changes, tingling sensations, tiredness or weakness, upset stomach, dizziness, and warm/cold temperature sensations. The U.S. Food and Drug Administration (FDA) approved naratriptan on February 11, 1998.

Side effects

Dizziness, drowsiness, tingling of the hands or feet, unusual tiredness, nausea, dry mouth and unsteadiness. If these effects persist or worsen, notify your doctor promptly. Unlikely but report promptly: chest pain/pressure, throat pain/pressure, unusually fast/slow/irregular pulse, one-sided muscle weakness, vision problems, cold/bluish hands or feet, stomach pain, bloody diarrhea, mental/mood changes, fainting. In the unlikely event you have a serious allergic reaction to this drug, seek immediate medical attention. Symptoms of a serious allergic reaction include: rash, itching, swelling, severe dizziness, trouble breathing.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Naratriptan". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE